A phase 2/3, randomized, open-label, parallel group, 2-arm, multicenter study investigating the efficacy and safety of intravenous administrations of anakinra, an interleukin-1(IL-1) receptor antagonist, added to standard of care, versus standard of care, in reducing hyper-inflammation and respiratory distress in patients with SARS- CoV-2 infection.

• Código protocolo: ANA-COVID-GEAS
• Código EudraCT: 2020-001825-29
• Grupo de investigación: Enfermedades Sistémicas
• Servicio: Medicina Interna
• Investigador/a principal:  Bujan Rivas, Segundo
• Patología: Certes malalties infeccioses i parasitàries
• Fase: Fase III
• Estado: Reclutando voluntarios